Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...
Bacterial Conjunctivitis Drugs Market is expected to reach US$ 4.9 Billion by 2036, Driven by Increasing Prevalence of Eye ...
AptarGroup, Inc. , a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and ...
A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to hereditary neuronal sodium ion channel mutationsAdolore's Kv7 voltage-gated ...
The FDA has cleared a mobile application that will connect with a next-generation multiple daily injection automated insulin ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset FocusTEL ...
Vetter, a globally operating CDMO, has completed several important steps in the ongoing development and upcoming launch of V-OVS® next.
The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...
The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback